Urine Samples for Lung Cancer Detection

Recruiting at 6 trial locations

Overseen By David Jones, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Memorial Sloan Kettering Cancer Center

Must not be taking: Immunosuppressants

Disqualifiers: Pregnant, Immune diseases, Cancer treatment, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

210 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new method to detect lung cancer using urine samples. Researchers employ trained animals to sniff out unique chemicals in urine that might indicate lung cancer. The goal is to develop a non-invasive method (no surgery or needles) for diagnosing lung cancer. Suitable participants for this trial include individuals diagnosed with lung cancer, those suspected of having it, or those without any signs of lung cancer. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research in non-invasive cancer detection.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are taking drugs that affect the immune system.

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores a unique method of detecting lung cancer using urine samples. Unlike traditional diagnostic methods like CT scans or biopsies, this approach utilizes a rat-based Animal Bioassay Platform (ABP) to identify specific volatile organic compounds (VOCs) associated with non-small cell lung cancer (NSCLC) in urine. This method is non-invasive and could potentially lead to earlier and more accessible cancer detection. By improving early detection, this technique could significantly enhance treatment outcomes and patient survival rates.

Who Is on the Research Team?

Gaetano Rocco, MD

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase I

Assessment of the ability of a rat-based ABP to detect NSCLC-specific VOCs in urine samples from subjects with and without NSCLC

Estimated 6 months

Phase II

Assessment of the ability of the ABP to detect NSCLC-specific VOCs in urine samples from subjects with suspected but undiagnosed NSCLC

Estimated 6 months

Follow-up

Participants are monitored for safety and effectiveness after the ABP test

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Urine Sample

How Is the Trial Designed?

Group I: patients diagnosed with NSCLC Experimental Treatment 1 Intervention

In phase I, the researchers will assess the ability of a rat-based ABP to detect the presence or absence of NSCLC-specific VOCs in urine samples from subjects with and without NSCLC. In phase II, the researchers will assess the ability of the ABP to detect the presence of NSCLC-specific VOCs in urine samples from subjects with suspected but undiagnosed NSCLC (clinical stage I to IIIA). Urine samples will be collected from 50 patients diagnosed with NSCLC and from 50 subjects without NSCLC for phase I and from 110 patients with suspected but undiagnosed NSCLC for phase II (total number of subjects = 210).

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials

1,998

Recruited

602,000+

EARLY Labs

Collaborator

Trials

1

Recruited

210+